AZM treatment increased RV-induced IFN-β and IFN-λ protein release and reduced viral progeny in patients with non-atopic asthma, and a similar trend was observed in atopic asthma, and regardless of eosinophilia. The gene discussed is IFNB1; the disease is Increased total eosinophil count.